About EyeSense
EyeSense is a Technology company based in Stockstadt Am Main (Germany) founded in 2006. Continuous glucose monitoring systems for diabetes management are developed. It operates on a HealthTech and Product-as-a-Service model in Technology and Healthcare sectors. EyeSense has raised $8.23 million across 3 funding rounds from investors including Qiagen, Life Sciences Partners and Lee’s PHARM. The company has 15 employees. EyeSense offers products and services including FiberSense Sensor and EyeSense App. Its focus areas include Medical Devices and Diabetes Management. Its legal entity is EyeSense GmbH.
Company details
Advanced medical technology for diabetes management is provided by EyeSense. Focus is placed on continuous glucose monitoring through innovative optical sensors. The FiberSense platform is designed for precision and sustainability, targeting Type-1 and Type-2 diabetes patients. Additional biometric data monitoring, such as ketones and cortisol, is planned for future expansion. The healthcare sector is served with solutions emphasizing reliability, discretion, and environmental responsibility. User-friendly systems with real-time alerts are integrated for seamless health management. Software updates are intended to ensure adaptability to evolving user needs.
- Headquarters Stockstadt Am Main, Germany
- Employees 15
- SectorsTechnologyHealthcare
- Email••••••••
- Phone•••• ••••
- Website eyesense.com
- Social LinkedIn
- Legal Name Eyesense Gmbh
- Total Equity Funding$8.23M (USD)
in 3 rounds
- InvestorsQiagen
& 5 more
- Employee Count15
Products & Services of EyeSense
EyeSense offers a comprehensive portfolio of products and services, including FiberSense Sensor and EyeSense App.
Continuous glucose monitoring is enabled by optical sensor.
Real-time glucose data is provided to users' smartphones.
Funding Insights of EyeSense
EyeSense has successfully raised a total of $8.23M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.23M
- Total Rounds 3
- First Round $8.23M
(Feb 2006)
- Investors Count 6
All 3 funding rounds of EyeSense with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2014 | Series C | – | – | ||
| Jan 2011 | Series B | – | – | ||
| Feb 2006 | $8.23M | Series A | – | BioMedPartners, Life Sciences Partners |
6 investors in total: 6 institutional.
Investors in EyeSense
EyeSense has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiagen, Life Sciences Partners and Lee’s PHARM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investment firm | rosettacapital.com | Aylesbury, United Kingdom | ||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Innovative biopharmaceutical products are developed to address unmet medical needs. | 2002 | leespharm.com | Hong Kong, China | |
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for EyeSense
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EyeSense
1 people are tracked at EyeSense (1 in leadership); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Achim Muller | Managing Director | Leadership |
Complete people profiles for EyeSense
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EyeSense
3 dated milestones of EyeSense across 8 years, from founding to its latest funding, stage changes and deals.
- Founded EyeSense is founded.
- Funding First funding round of $8.2M.
- Funding Latest funding round, Series C,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eyesense
Complete news archive for EyeSense
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EyeSense
EyeSense was founded in 2006.
EyeSense is headquartered in Stockstadt Am Main, Germany. It is registered at Stockstadt Am Main, Bavaria, Germany.
EyeSense is a funded company, having raised a total of $8.23M across 3 funding rounds to date. The company's 1st funding round was a Series A of $8.23M, raised on Feb 2006.
EyeSense has 15 employees.
Advanced medical technology for diabetes management is provided by EyeSense. Focus is placed on continuous glucose monitoring through innovative optical sensors. The FiberSense platform is designed for precision and sustainability, targeting Type-1 and Type-2 diabetes patients. Additional biometric data monitoring, such as ketones and cortisol, is planned for future expansion. The healthcare sector is served with solutions emphasizing reliability, discretion, and environmental responsibility. User-friendly systems with real-time alerts are integrated for seamless health management. Software updates are intended to ensure adaptability to evolving user needs.
EyeSense offers FiberSense Sensor and EyeSense App.
EyeSense has 6 investors. Key investors include Qiagen, Life Sciences Partners, Lee’s PHARM, Rosetta Capital, and BioMedPartners.
EyeSense operates through Eyesense Gmbh.